Trials / Completed
CompletedNCT04606407
Inhaled NO for the Treatment of Viral Pneumonia in Adults
Prospective, Open-label, Randomized, Multi-Center Study for Safety and Efficacy Evaluation of Inhaled Nitric Oxide (NO) Given Intermittently to Adults With Viral Pneumonia
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Beyond Air Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this multi center, open label, randomized, study is to obtain information on the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with viral pneumonia
Conditions
- Viral Pneumonia
- Nitric Oxide
- Respiratory Disease
- Pneumonia, Viral
- Inhaled Nitric Oxide
- Covid19
- SARS-CoV Infection
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | LungFit™ | Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments) |
Timeline
- Start date
- 2020-11-25
- Primary completion
- 2022-08-07
- Completion
- 2022-08-07
- First posted
- 2020-10-28
- Last updated
- 2022-12-16
Locations
3 sites across 1 country: Israel
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04606407. Inclusion in this directory is not an endorsement.